Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Allogene Therapeutics (ALLO) FCF Margin: 2021-2025

Historic FCF Margin for Allogene Therapeutics (ALLO) over the last 5 years, with Sep 2025 value amounting to 8,679.94%.

  • Allogene Therapeutics' FCF Margin fell 3586406.00% to 8,679.94% in Q3 2025 from the same period last year, while for Sep 2025 it was 18,859.79%, marking a year-over-year decrease of 60378878.00%. This contributed to the annual value of -913,609.09% for FY2024, which is 66176804.00% down from last year.
  • As of Q3 2025, Allogene Therapeutics' FCF Margin stood at 8,679.94%, which was down 40.58% from 14,606.72% recorded in Q2 2025.
  • In the past 5 years, Allogene Therapeutics' FCF Margin registered a high of 45,623.46% during Q4 2024, and its lowest value of -282,477.27% during Q2 2023.
  • In the last 3 years, Allogene Therapeutics' FCF Margin had a median value of -108,450.03% in 2025 and averaged -112,244.70%.
  • In the last 5 years, Allogene Therapeutics' FCF Margin plummeted by 24,527,743bps in 2022 and then skyrocketed by 30,223,298bps in 2024.
  • Allogene Therapeutics' FCF Margin (Quarterly) stood at -61.03% in 2021, then plummeted by 24,527,743bps to -245,338.46% in 2022, then tumbled by 1,127,106bps to -256,609.52% in 2023, then surged by 30,223,298bps to 45,623.46% in 2024, then crashed by 3,586,406bps to 8,679.94% in 2025.
  • Its FCF Margin was 8,679.94% in Q3 2025, compared to 14,606.72% in Q2 2025 and 35,352.00% in Q1 2025.